20 January 2021 - Sanofi’s nirsevimab has been awarded a Promising Innovative Medicine designation by the Medicines and Healthcare Products Regulatory Agency in the UK for the prevention of respiratory syncytial virus associated lower respiratory tract infections.

Nirsevimab is an extended half-life monoclonal antibody currently being investigated as a passive immunisation for the prevention of lower respiratory tract infections caused by respiratory syncytial virus in all infants from birth and up to 12 months of age.

Read Pharma Times article